

Global Journal of Medicine and Public Health www.gjmedph.org

Platinum based doublet cross over therapy for advanced stage non small cell lung cancer? A better survival option

Rajiv Garg 1, S Saheer2, Ghulam Hassan 3, Rashmi Upadhyay 4.

1: Professor, 2: Junior Resident, 3. Post-doctoral Trainee, 4: Junior Resident, Department of Pulmonary Medicine, : CSM Medical University, UP, Lucknow, India

Address for correspondence:

Prathima S*, CSBR Prasad**, Udayakumar M***, Narayanaswamy M****

*Assistant Professor in Pathology, ** Associate Professor in Pathology, *** Professor in Pathology, **** Professor in Obstetrics & Gyneacology, Sri Devaraj Urs Medical College, Tamaka, Kolar- 563 101. Karnataka.

ABSTRACT

Platinum based doublet chemotherapy namely the cisplatin/carboplatin based etopiside or gencitabine therapy forms the therapy of choice, for patients with advanced non small cell carcinoma of the lung. Here we report two cases were unusual cross over was done from gencitabine-to cisplatin-doublet chemotherapy resulting in unexpectedly better clinical and radiological response.

Keywords: Non small cell lung cancer, platinum based doublet chemotherapy, cross over therapy.

Corresponding Author: Rajiv Garg. Professor, Department of Pulmonary	medicine
CSM Medical University, UP, Lucknow, India-226003	
Email: rajivkgmc@gmail.com.	

Funding: None	Conflict o
Introduction	of 3 months of
Lung cancer is the leading cause of cancer related	homogeneous
mortality in both men and women throughout the	(Figure 1a), a
world. In 2007, an estimated 1.5 million new cases of	measuring 6.5
lung cancer were diagnosed globally, accounting for	of left upper
approximately 12% of the global cancer burden ¹ . The	the lesion wa
treatment of NSCLC is surgery for early stages,	TTF 1 positiv
chemotherapy with concurrent radiation for locally	diagnosed to
advanced cancers, and palliative chemotherapy for	adeno and the
metastatic disease ² . Cisplatin based doublet	Karnofsky pe
(Gemcitabine /Etoposide) chemotherapy is the	ECOG score
treatment of choice, and, cisplatin plus Gemcitabine	$(1250 mg / m^2)$
doublet having the better toxicity profile ³ . We are	After two cyc
reporting here our experience with two patients in	cisplatin plus
whom we were forced to switch over from	cycles of Cis
Gemcitabine -to -Cisplatin doublet regimen due to	completion
interruption of supply of Gemcitabine from our	radiological (
hospital.	karnofsky of 9

Case 1: A 40 -year- old ex-smoker presented with complaints of dry cough, chest pain and hemoptysis

Conflict of interest: None

duration. Chest X ray PA view revealed s opacity in left upper and midzone and CT Thorax showed attenuated lesion 5x5x3 cm in the apico-posterior segment r lobe(Figure 1b).CT guided biopsy of as done and its histopathology revealed ve adenocarcinoma. Thus the patient was o have bronchogenic carcinoma type e TNM staging was III B T₄ N₂M₀. His performance status score was 60 and was 2. He was started on Gemcitabine ²) plus Cisplatin (100mg/m^2) regimen. cles we were forced to switch over to s etoposide. Patient then completed four splatin and etoposide (30 mg/m^2) . On of six cycles there was dramatic (Figure 1c) and clinical response with karnofsky of 90 and ECOG of 0.

Case 2: A 60 –year old smoker and alcoholic patient was admitted in our department with complaints of

hemoptysis of one month duration. His admission chest radiograph revealed prominent left hilum (Figure 2a) and CT Thorax showed nodular lesion in superior segment of left lower lobe (Figure 2b). Bronchoscopy was done and transbronchial lung biopsy from superior segment of left lower lobe revealed squamous cell carcinoma. Thus the patient was diagnosed to have bronchogenic carcinoma type squamous with TNM staging of III A $T_2N_2M_0$. His Karnofsky performance Status score was 40 and ECOG score was 3.He was planned concurrent chemo-radiotherapy followed by surgical resection, but he refused both radiotherapy and surgery , and was put on Gemcitabine($1250mg/m^2$) and Cisplatin($120mg/m^2$) therapy. Just like our previous patient, after two cycles we were forced to shift over to etoposide ($50 mg/m^2$) from Gemcitabine. On completion of six cycles he also showed good clinical recovery (Figure 2c) with karnofsky of 80 and ECOG of 1.

Figure 1:Intial chest skiagram (a) showing homogeneous nodular opacity in left upper and midzones ,admission computed tomography(b) showing rounded soft tissue attenuated lesion measuring $6.5 \times 5 \times 3$ cm in the left apicoposterior and postchemotherapy one(c) revealing thick walled cavity with adjacent fibrosis in the same segment.





Figure 2: Admission chest x ray (a) showing prominent left hilum (arrow), computed tomography (b) revealing $4.4 \times 4 \times 3$ cm nodular lesion in superior segment of left lower lobe (arrow) and post six cycles computed tomography depicting (c) residual lesion.



Discussion

The choice of treatment in a case of lung cancer depends on the type of lung cancer, the size and location of tumor, whether or not the tumour has spread outside the lungs, the patient's age and general health status. Treatment options include radiotherapy, chemotherapy and surgery. Newer treatment modalities include targeted therapy, cryosurgery, laser surgery, photodynamic therapy, electrocautery and internal radiation. Non Small Cell Lung Cancer (NSCLC) with stages I and II are usually treated with surgery. In patients with stages I and II were surgery can't be done due to poor lung reserves radiation therapy is used. Chemotherapeutic regimens are usually reserved for advanced stages like III and IV or as adjuvant therapy, that is, to be used after surgery or as neoadjuvant therapy, which is treatment before surgery.

Platinum-based chemotherapeutic agent is the standard care of treatment in patients with NSCLC especially in advanced disease (stages III and especially IV)^{4,5}. Combination regimens are usually preferred and this often includes a platinum drug like

cisplatin along with etoposide or newer agents like docetaxel, gemcitabine, pemetrexed or vinorelbine⁵. Even after extensive search in pub med database we were unable to find any literature on gemcitabine-to cisplatin-doublet cross over chemotherapy. But is this just a matter of chance or is it really a method worth following, needs to be evaluated on large scale by further randomised studies, which will be a real boon for the already ailing cancer patient and their families.

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225–249.

2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA.Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83:584-94.

3.Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, *et al*.Platinumbased and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001; 357:1478-84.

4. Georgoulias V, Papadakis E, Alexopoulos A, et al: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial. Lancet. 2001, 357: 1478-1484.

5. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004, 350: 379-392.



Access This Article Online

Quick Response Code:



Website: www.gjmedph.org

GJMEDPH, Vol 1(4) July- August 2012